hotspot -WSS

hotspot

author：explore 2025-09-28 00:47:29 - browse：988

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Why Eli Lilly’s earnings didn’t quite live up to the hype

WSS

Report cites 'urgent' need to recruit more diverse clinical trial participants

As health system earnings go up, health insurance stocks go down

HHS's proposed rule does nothing to address the climate crisis

Warren pushes Witty on UnitedHealth's control over physicians

Ebola vaccine can save some who are already sick, per new study

HHS's proposed rule does nothing to address the climate crisis

Wikipedia

hotspot

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Resistance to opioid

What does generative AI mean for health care? We asked experts

Novel spinal cord stimulator treats paralysis without surgery

Walensky prepares to leave CDC — and Congress — behind

Deliver public health messages at the right time

Activists slam private health insurers over coverage restrictions

Has Bernie Sanders reached the limit of his pharma bullying effort?

Sports medicine is finally prioritizing gender equality

AltruBio raises $225 million to develop ulcerative colitis drug

Wikipedia

Report cites 'urgent' need to recruit more diverse clinical trial participants

As billionaires fund anti

Juul documents reveal insider tactics on political lobbying

Too many hospitalized Covid

Too many hospitalized Covid

Resistance to opioid

entertainment

Wikipedia

hotspot

explore